Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade

Launched by THE UNIVERSITY OF HONG KONG · Jun 16, 2009

Keywords

ClinConnect Summary

This will be an open-label pilot study in which IgAN patients with persistent proteinuria despite maximum dose of ARB treatment will be assigned to receive Aliskiren. There is the optional addition of other anti-hypertensive agents to achieve an optimal target blood pressure of \<130/80 mmHg.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female 18 - 70 years of age
• • Histologic diagnosis of IgA nephropathy
• • Proteinuria \> 1 g/day or UPC \> 1 mg/mg or 113 mg/mmol at least twice
• • Receiving treatment with the maximum dose of ARB for at least 3 months
• • Patients who are willing to give written, informed consent
• Exclusion Criteria:
• • eGFR \< 15 ml/min/1.73 sq.m
• • UPC \>5000 mg/g or 570 mg/mmol, or \<500 mg/g or 57 mg/mmol
• • Serum K+ \> 5.2 mmol/L
• • Presence of bilateral renal artery stenosis
• • Presence of diabetes mellitus
• • Renal histology showing pathologies other than IgAN
• • Known allergy to ARB or DRI
• • Patients on ARB/ACEi combination within 12 weeks of randomization
• • Concurrent treatment with corticosteroids, Nsaid, or immunosuppressant
• • Patients with connective tissue disease or obstructive uropathy
• • Patients with malignancy or conditions severely limiting life expectancy
• • Female who are pregnant or intending to conceive
• • Female of child-bearing age unwilling to practice contraception
• • Patients who are unable to give informed consent
• • Patients simultaneously participating in another study